Research Insight
Eisai and UCLommence preparations for phase i clinical studies in Alzheimer’s Disease for Novel Anti-Tau Antibody
Eisai Co., Ltd and University College London announced that they have commenced preparations for Phase I clinical studies on E2814 The first...
Research Insight
ADC Bio secures additional equity round investment
ADC Biotechnology , announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate...
Research Insight
Protagen AG collaborates with UCSF to study better immuno-profiling of cancer patients receiving immunotherapy
Protagen AG has announced the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen’s SeroTag® technology to investigate the...
Articles
The Falsified Medicines Directive – are you ready?
The Falsified Medicines Directive 2011/62/EU, which is due for adoption in February 2019, will require pharmaceuticalcompanies to apply serialisation codes to every applicable pack (OTC...
Articles
Stem Cell and Regenerative Therapies for Hearing Loss
The year 2018 marks a notable milestone in the history of stem cell and regenerative medicine. It was twenty years ago, in 1998, that James...
Articles
High quality ophthalmic consumables at affordable prices to developing countries: An Aurolabs Case Study
Aurolab, the manufacturing division of Aravind Eye Hospital, at Madurai, Tamil Nadu that supplies high quality ophthalmic consumables at affordable prices to developing countries.
Though its...
Research Insight
Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
Organovo Holdings, Inc announced that the U.S. FDA granted orphan drug designation for the Company’s treatment of alpha-1 antitrypsin deficiency (“A1AT”) with its 3D bioprinted...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.